Caracterización molecular de genes de virulencia (lmb, bca y rib) y de resistencia a macrólidos (ermB, ermTR y mefA) en aislamientos clínicos de Streptococcus agalactiae

Angie Pulido-Colina; Javier Soto Pastrana; Ester Valencia-Bazalar; Milagros Zavaleta Apestegui

doi:10.17843/rpmesp.2021.384.8726

Authors

Angie Pulido-Colina Universidad Nacional Federico Villarreal, Lima, Perú. Universidad Nacional Mayor de San Marcos, Lima, Perú. Tecnólogo médico https://orcid.org/0000-0002-7619-4353
Javier Soto Pastrana Hospital Nacional Docente Madre-Niño San Bartolomé, Lima, Perú. Tecnólogo médico https://orcid.org/0000-0001-9534-5746
Ester Valencia-Bazalar Instituto de Medicina Tropical «Daniel A. Carrión», Departamento Académico de Microbiología Médica. Facultad de Medicina. Universidad Nacional Mayor de San Marcos, Lima, Perú. Tecnólogo médico https://orcid.org/0000-0002-4059-9842
Milagros Zavaleta Apestegui Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Perú. biólogo molecular https://orcid.org/0000-0002-2743-9035

DOI:

https://doi.org/10.17843/rpmesp.2021.384.8726

Keywords:

Streptococcus agalactiae, PCR, Genes, Virulence, Drug Resistance, Macrolides, Microbial Sensitivity Test

Abstract

The aim of the study was to molecularly identify virulence and macrolide resistance genes in clinical isolates of Streptococcus agalactiae (GBS), recovered in 2019 from vaginal discharge (n=9) and urine (n=22), from two health facilities in Lima. Identification and antimicrobial susceptibility were determined by the Vitek® 2 automated system, identification was confirmed phenotypically; macrolide resistance was determined by the D-test method. Identification of virulence genes (lmb, bca and rib) and macrolide resistance genes (ermB, ermTR and mefA) was carried out by polymerase chain reaction (PCR). The predominant macrolide resistance phenotype and genotype were cMLSb (12/31) and ermB (11/31); the most frequent virulence gene was lmb (23/31). All were sensitive to penicillin, ampicillin and vancomycin. These findings show the need to implement molecular epidemiology studies that allow adequate knowledge and follow-up of GBS in Peru.